Quantcast

Latest Abagovomab Stories

2009-03-23 07:00:00

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. "We are pleased that the FDA...

2009-03-20 10:59:00

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. The principal investigator for the trial is Dr. Kevin Harrington of The...

2008-11-03 09:00:40

Oncolytics Biotech has announced positive interim results in its Phase I and Phase II UK combination Reolysin and paclitaxel/carboplatin clinical trials for patients with advanced cancers. Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response, the company said. These results appear to confirm preclinical evidence of synergy for Reolysin and platinum/taxane combinations. A US Phase II trial has now been opened in this patient...

2008-10-30 03:00:13

OXiGENE, a biopharmaceutical company, has reported positive interim results from an ongoing Phase II study of Zybrestat in patients with platinum-resistant ovarian cancer. The company said that 10 of 34 evaluable patients (29%) enrolled to date in the ongoing, single-arm, Simon two-stage design study evaluating the combination of Zybrestat and chemotherapy (carboplatin and paclitaxel) had partial responses as measured by tumor imaging and/or ovarian cancer biomarker (CA-125) criteria. An...

2008-10-01 12:00:31

ImClone Systems has announced that the first patient has been treated in its disease-directed Phase II clinical trial of IMC-1121B in patients with advanced ovarian cancer. This multicenter, open-label Phase II single-arm study is enrolling women with persistent or recurrent advanced ovarian, fallopian tube, and primary peritoneal epithelial cancers following at least one platinum-containing chemotherapy regimen. Approximately 55 patients are expected to be enrolled at various centers...

2008-09-12 09:00:09

Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research, has started a Phase II clinical trial in the US evaluating the safety and efficacy of its drug candidate, IT-101, in patients with platinum-sensitive ovarian cancer. The study is open for enrollment. This Phase II study is designed to determine if IT-101 treatment initiated after a standard second line course of platinum chemotherapy in patients who have stable disease, a partial response or a complete response can...

2008-09-09 12:00:42

Oncolytics Biotech has initiated patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers...

2008-07-18 09:01:12

Biovest International, a majority-owned subsidiary of Accentia Biopharmaceuticals, has announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase III fast-tracked clinical trial of BiovaxID for the treatment of indolent follicular non-Hodgkin's lymphoma, an often fatal blood cancer. Biovest reported on two clinically relevant data points - overall median disease-free survival data as measured up to 80 months; and disease-free survival data...

2008-06-27 12:02:13

By Jason Gertzen, The Kansas City Star, Mo. Jun. 27--Local ovarian cancer patients soon will begin receiving new treatments, signaling advances both in the fight against the disease and in the region's bioscience aspirations. The University of Kansas Cancer Center on Thursday announced the official start of work to test a new ovarian cancer drug. The Phase 1 clinical trial marks the first time that a drug developed by KU scientists is remaining here for this development phase. In...

2007-02-21 00:00:08

AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces it has executed a collaboration and production agreement with Cancer Treatment Centers of America, Inc. (CTCA) for AVAX's O-Vax, the AC Vaccine Therapeutic for the treatment of Ovarian Cancer and for the production of CTCA's activated natural killer (NK) cell technology for the treatment of various human cancers. AVAX intends to activate a Phase I/II IND for the treatment of Stage III & IV Ovarian Cancer patients who have...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related